8 completed, 2 terminated. 9 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Terminated 1 |
| Early Phase 1 | 1 | Terminated 1 |
Follow Recurrent Intraocular Melanoma: new trials by email Literature Review of Recurrent Intraocular Melanoma trials Research Report on Recurrent Intraocular Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases ipilimumab, yttrium Y 90 glass microspheres, laboratory biomarker analysis - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Early Phase 1 | Terminated | Case Comprehensive Cancer Center | 6 | 2012-12-01 | 2016-03-10 |
| Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery axitinib, laboratory biomarker analysis - Extraocular Extension Melanoma, Metastatic Intraocular Melanoma | Phase 2 | Terminated | Roswell Park Cancer Institute | 25 | 2012-01-01 | 2018-05-09 |
| Cixutumumab in Treating Patients With Metastatic Melanoma of the Eye Cixutumumab, Laboratory biomarker analysis - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | National Cancer Institute (NCI) | 18 | 2011-08-01 | 2020-02-19 |
| Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye carboplatin, paclitaxel, sorafenib tosylate - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 25 | 2011-02-01 | 2014-07-31 |
| Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | Case Comprehensive Cancer Center | 38 | 2009-11-11 | 2019-02-26 |
| VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery ziv-aflibercept, pharmacological study - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 41 | 2007-06-01 | 2018-05-24 |
| Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma carboplatin, paclitaxel, bortezomib - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2005-10-01 | 2013-03-05 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma vorinostat - Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 32 | 2005-09-01 | 2019-01-29 |
| Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma gp100 antigen, tyrosinase peptide, recombinant MAGE-3.1 antigen - Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size | Phase 2 | Completed | University of Southern California | 42 | 2004-05-01 | 2014-05-22 |
| Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye gp100 antigen, interleukin-2, MART-1 antigen - Extraocular Extension Melanoma, Recurrent Intraocular Melanoma | Phase 2 | Completed | National Cancer Institute (NCI) | 2001-02-01 | 2024-03-04 |
Uveal Melanoma (10) · Melanoma (5) · Eye Neoplasms (1) · Neoplasms (1)
Eye Diseases (10) · Neoplasms by Histologic Type (10) · Neoplasms by Site (10) · Neoplasms, Germ Cell and Embryonal (10) · Neoplasms, Nerve Tissue (10) · Neuroectodermal Tumors (10) · Neuroendocrine Tumors (10) · Nevi and Melanomas (10) · Uveal Diseases (10) · Uveal Neoplasms (10) · Eye Neoplasms (9) · Neoplasms (9) · Melanoma (5) · Skin Diseases (5) · Skin Neoplasms (5)
Carboplatin (2) · Paclitaxel (2) · montanide ISA 51 (2) · Axitinib (1) · Bortezomib (1) · CTLA-4 Antigen (1) · Dacarbazine (1) · Interferon alpha-2 (1) · Interleukin-2 (1) · Introns (1) · Ipilimumab (1) · MAGEA3 protein, human (1) · MART-1 Antigen (1) · ProMune (1) · Sorafenib (1)
National Cancer Institute (NCI) (6) · Case Comprehensive Cancer Center (2) · Roswell Park Cancer Institute (1) · University of Southern California (1)
United States (10) · Canada (1)
Ahmad Tarhini (1) · Ana Aparicio (1) · Francesco M. Marincola (1) · Gary Croghan (1) · Jeffrey Weber (1) · Matuesz Opyrchal, MD (1) · Michael McNamara, MD (1) · Naomi Balzer-Haas (1) · Sapna Patel (1) · Yogen Saunthararajah, MD (1)
PMID 23226204, PMID 24464266, PMID 31371315
N01CM00039 (1), N01CM62203 (1), N01CM62205 (1), N01CM62209 (1), P30CA016056 (1), P30CA016672 (1), P30CA033572 (1), U10CA032102 (1)